Reader 100

CAMPTON Biochip Reader helps to improve patient care and treatment.

With just a few microlitres of blood, our Biochip Reader delivers reliable and fast diagnosis on a wide variety of diseases.

Advantages of the new CAMPTON Biochip-Reader-System

Common diagnostic tests usually require laboratories and excessive equipment as well as extensively trained personnel to deliver results in slow and time-consuming processes (e.g. 1-3 days to get results).

Portable diagnostic devices like the CAMPTON Reader 100 overcome those restrictions: The fully automated platform performs sample extraction, preparation, (amplification*) and detection all within the self-contained single-use “laboratory in a cartridge” making it especially easy to perform with minimal equipment and training.

The CAMPTON Reader 100 provides rapid test results within minutes, enabling cost and time-effective diagnostics. The consolidated assay design allows the testing for both serological and molecular biological assays reducing the need for multiple testing platforms. In contrast to competitors who often use optics to detect the test results, our newly developed CAMPTON technology uses electrical signals, making the CAMPTON Reader 100 technology more robust and therefore suitable for the use in nearly any climate and even in the most remote places.

Possible applications for the Biochip System

Next to the wide range of possible customized applications, the following established tests are currently available including all required assay reagents in ready-to-use-kits for the biochip system:

  • SARS-CoV-2 (serological)
  • Vaccination Status (serological)
  • CRP (serological)
  • Customer-specific tests

CAMPTON Diagnostics delivers innovative assays on an easy-to-use platform for point-of-care diagnostics. We are committed to expanding our test menu to cover more infectious diseases and biomarkers with current testing panels in the pipeline:

Covid-19 (serological and molecular biological) and MRSA (molecular biological), both expected to be released in 2020/2021.

Our first product is focused on the aforementioned tests – but we can quickly address any disease detected from antibodies, DNA or RNA!

The volume production of the first reader version is planned to start in Q4 2020 and a miniaturized reader version for enhanced mobile diagnostics is already under development.

devt1